Peptide Biosimilar Development Trends: What to Expect Through 2030

What Is a Peptide Biosimilar and Why Is the Market Growing?

A peptide biosimilar is a version of an approved peptide drug that is highly similar to the original but made by a different company. It is not an exact copy because peptides are too complex to replicate perfectly. But it must be close enough to work the same way in patients.

The market for peptide biosimilars is growing fast as major peptide drugs lose patent protection. Companies that were once too small to develop new peptide drugs can now compete by making biosimilar versions of proven products.

Expert Quote: "Peptide biosimilars are not just cheaper copies. They represent a new level of manufacturing precision and analytical rigor that raises the bar for the entire industry." - VP of Regulatory Affairs, Global Biosimilar Manufacturer

Why Peptide Biosimilars Are Different From Small Molecule Generics

When a small molecule drug goes off patent, any company can make an exact copy using the same chemical structure. This is called a generic drug.

Peptides are different. They are larger and more complex than small molecules. Even tiny changes in the manufacturing process can change how the peptide folds, how pure it is, or how stable it is. This is why the FDA and EMA require more evidence before approving a peptide biosimilar.

The FDA's biosimilar pathway was created by the Biologics Price Competition and Innovation Act (BPCIA) of 2010. This law set up a clear route for companies to develop biosimilars of complex drugs, including larger peptides.

A single amino acid substitution or oxidation event during manufacturing can shift a peptide's receptor binding affinity by more than 50%, which is why biosimilar approval demands far more analytical data than small molecule generics.

The Current State of the Peptide Biosimilar Market

Several peptide-based drugs have already faced biosimilar competition. This has brought prices down and expanded patient access significantly.

Reference Drug	Primary Indication	Biosimilars Status (2026)
Insulin (various)	Diabetes	Multiple biosimilars approved globally
Somatropin (growth hormone)	Growth disorders	Biosimilars approved in US and EU
Teriparatide (Forteo)	Osteoporosis	Biosimilars approved in US and EU
Leuprolide acetate	Prostate cancer, endometriosis	Multiple competitors available
Glucagon-like peptides (GLP-1s)	Diabetes and obesity	Biosimilars in development pipeline
Exenatide (Byetta)	Type 2 diabetes	Generic and biosimilar versions available

The GLP-1 category is the most watched right now. Drugs like semaglutide and tirzepatide have become blockbuster products. When their patents expire, there will be enormous demand for biosimilars.

Regulatory Requirements for Peptide Biosimilar Approval

Getting a peptide biosimilar approved requires a large body of evidence. The process is shorter and cheaper than getting a new drug approved, but it is still complex and expensive.

Analytical Similarity You must show through rigorous testing that your biosimilar has the same amino acid sequence, same peptide structure, and same purity profile as the reference product. This requires advanced analytical tools like mass spectrometry, circular dichroism, and HPLC.

Pharmacokinetic Studies You need to show that your biosimilar reaches the same blood levels as the reference drug when given to healthy volunteers. This usually requires a Phase 1 clinical study.

Clinical Equivalence For some peptide biosimilars, regulators also require evidence from patients that the drug works the same way clinically. This can mean a full Phase 3 trial or extrapolation from the reference drug's data.

Immunogenicity Testing One of the biggest risks with any peptide drug is that the immune system might react to it. Biosimilars must show that they do not cause more immune reactions than the original.

Key Analytical Challenges in Peptide Biosimilar Development

Proving similarity between two peptide products is harder than it sounds. Here are the main challenges.

Higher-Order Structure You must show that your peptide folds the same way as the reference product. Techniques like NMR, CD spectroscopy, and X-ray crystallography are used for this.

Post-Translational Modifications Some therapeutic peptides are modified after synthesis (for example, amidated at the C-terminus). You must show that these modifications are identical to the reference.

Impurity Profiling Your biosimilar must have the same impurity profile as the reference, or you must show that your impurities are not clinically meaningful. This is one of the most time-consuming parts of the development process.

Reference Product Sourcing To run comparison studies, you need to buy the original drug from multiple markets and multiple lots. This costs money and takes time.

Market Size and Growth Projections

The global peptide biosimilar market is growing faster than most other segments of the pharmaceutical industry.

Year	Estimated Market Value (USD)	CAGR
2022	$4.2 billion	-
2024	$5.8 billion	17.5%
2026	$8.0 billion	17.2%
2028	$10.9 billion	16.8%
2030	$14.5 billion	15.3%

Growth is being driven by the expiry of key peptide patents, healthcare payer pressure to reduce drug costs, and improving manufacturing capabilities in emerging markets.

Where Is Biosimilar Peptide Development Happening?

Development activity is concentrated in a few key regions, but the landscape is shifting.

United States The FDA's biosimilar pathway has matured and approvals are accelerating. US companies and CDMOs are building more peptide manufacturing capacity.

Europe The EMA was the first major regulator to approve biosimilars (in 2006). Europe remains a leader and has approved more peptide biosimilars than any other region.

India and China Both countries have built significant peptide manufacturing capability. Indian and Chinese companies are developing biosimilars for global markets and becoming major competitive forces.

South Korea Korean biotechs like Celltrion have become global leaders in biosimilars. Several are now expanding into peptide-specific biosimilar development.

India is one of the largest producers of generic and biosimilar peptide APIs in the world. Companies there often combine low-cost manufacturing with increasingly sophisticated analytical and regulatory capabilities.

Competitive Strategies for Peptide Biosimilar Companies

With so many players entering the space, differentiation is key. Here are the strategies that top companies are using.

1. Speed to Market Filing first in key markets gives you a significant pricing advantage. Companies are investing in faster analytical development and regulatory strategy teams to shorten timelines.

2. Manufacturing Quality Superior purity and batch-to-batch consistency can be a competitive differentiator. Companies that consistently produce cleaner products win formulary positions.

3. Device Innovation For self-administered peptide biosimilars (like insulin or GLP-1s), better delivery devices (autoinjectors, pens) can win market share even when the drug itself is similar to competitors.

4. Interchangeability Designation In the US, an "interchangeable" biosimilar can be substituted for the reference product by a pharmacist without consulting the prescribing doctor. Getting this designation significantly boosts market uptake.

Workforce Needs in the Peptide Biosimilar Sector

The growth of the peptide biosimilar market is creating strong demand for specialized talent. Companies need experts in analytical characterization, regulatory affairs, and peptide manufacturing.

Finding people who understand both the scientific complexity of peptide biosimilars and the regulatory requirements for biosimilar approval is especially hard. This is one of the most talent-constrained areas in the entire pharmaceutical industry.

For teams building out their peptide biosimilar capabilities, bringing on a qualified GMP auditor is often the first priority. See our guide on recruiting a peptide GMP auditor for help finding the right person.

You may also want to explore outsourcing options for early-stage analytical work. Our article on outsourcing peptide degradation studies covers how to find and manage a qualified CRO partner.

External Resource: FDA Biosimilar Development Guidance

The FDA has published comprehensive guidance on biosimilar development and approval. You can access the full guidance documents at FDA Biosimilar Development.

---

Frequently Asked Questions

What makes a peptide biosimilar different from a generic drug? Generic drugs are exact chemical copies of small molecule drugs. Peptide biosimilars are highly similar but not identical to the reference peptide. The manufacturing process affects the final product, so regulators require more testing to prove similarity.

Which peptide drugs face biosimilar competition right now? Insulin, growth hormone (somatropin), teriparatide, and leuprolide acetate all have approved biosimilars or generics. The GLP-1 receptor agonist market is the next major battleground.

How long does it take to develop a peptide biosimilar? Typically 7 to 10 years from start to approval, though this is shorter than developing a new drug. The analytical and regulatory similarity work takes most of that time.

What is the FDA's process for approving a peptide biosimilar? Companies submit a 351(k) application under the Biologics Price Competition and Innovation Act. The FDA reviews analytical similarity data, pharmacokinetic studies, and sometimes clinical data before granting approval.

Are peptide biosimilars as safe and effective as the original drugs? Yes. Regulatory approval requires proof that a biosimilar has no clinically meaningful differences from the reference product in terms of safety, purity, and effectiveness.

What is the biggest market opportunity in peptide biosimilars right now? GLP-1 receptor agonists like semaglutide and liraglutide represent the single largest opportunity as their patents begin to expire. The global market for these drugs is worth tens of billions of dollars annually.

How are companies reducing the cost of peptide biosimilar development? Key cost reduction strategies include better analytical tools that reduce the need for large clinical trials, platform technologies that can be reused across multiple biosimilar programs, and outsourcing to lower-cost manufacturing regions.